GSK just made its first big move under new boss Luke Miels—and it’s a chunky one. The FTSE 100 pharma giant is acquiring US biotech Rapt Therapeutics for $2.2bn (£1.6bn), nearly doubling the California firm’s share price overnight. Why the premium? GSK’s betting big on ozureprubart, Rapt’s experimental food allergy drug that could shake up a market with serious unmet needs. With trial data landing in 2026, this deal signals GSK’s appetite for high-potential pipeline assets. Here’s what you need to know.
What’s GSK Actually Buying?
At $58 per share—almost double Rapt’s $33.81 Nasdaq closing price—GSK’s paying $1.9bn upfront for global rights to ozureprubart, excluding mainland China, Hong Kong, Taiwan, and Macau. The drug targets inflammatory and immunologic diseases, specifically food allergies, where treatment options remain pretty thin on the ground.
Rapt specialises in therapies for immune-related conditions, and ozureprubart is their star asset. GSK’s chief scientific officer Tony Wood called it “another promising new, potential best-in-class treatment” that could deliver “sustained protection to patients.”
Deal’s expected to close in Q1 2026, assuming regulators don’t pump the brakes.
Why Food Allergies Matter Right Now
Food allergies affect millions globally, yet effective treatments remain scarce. Current options mostly involve strict avoidance and emergency interventions—hardly ideal for patients seeking normal lives.
Ozureprubart represents a different approach: sustained protection rather than reactive management. If trial data in 2026 proves positive, GSK could be sitting on a blockbuster in a market crying out for innovation.
Tony Wood emphasised the drug “addresses validated targets and where there is clear unmet medical need”—pharma speak for “this could actually help people and make money.”
Luke Miels Makes His Mark
This acquisition marks the first major deal for GSK’s new chief executive Luke Miels, who only recently took the reins. Starting with a $2.2bn bet sends a clear message: GSK’s hunting for high-impact pipeline additions, not playing it safe.
Rapt’s president and CEO Brian Wong noted the deal gives his company access to GSK’s “resources and infrastructure” plus “global development and commercialisation capabilities”—the muscle needed to take a promising drug to market worldwide.
Not everyone’s convinced yet. GSK shares dropped 1.24% to 1,793.49p following the announcement, suggesting investors want to see the trial data before celebrating.
The HIV Venture Reshuffle
In related news, GSK’s also reshuffling its HIV joint venture ViiV Healthcare. Japanese pharma Shionogi & Co is buying out Pfizer’s 11.7% stake for $2.1bn, boosting its own holding from 10% to 21.7%.
Pfizer’s walking away with $1.8bn whilst GSK maintains its 78.3% controlling stake. ViiV chair David Redfern called it a move to “simplify ViiV’s shareholder structure” whilst continuing collaboration with Shionogi on long-acting injectable HIV treatments.
Translation? Fewer cooks in the kitchen, cleaner ownership structure, same strategic direction.
What Happens Next
GSK now owns the rights to develop and commercialise ozureprubart globally (outside Greater China). They’ll also handle royalty payments owed to Rapt’s Chinese partner, Shanghai Jeyou Pharmaceutical Co.
Trial data expected in 2026 will determine whether this $2.2bn gamble pays off. Positive results could validate Miels’ aggressive start and position GSK as a leader in food allergy treatment. Disappointing data? That share price dip might look prophetic.
Either way, GSK’s signalling it’s back in acquisition mode—and willing to pay premiums for drugs with genuine market potential.
Key Takeaways
GSK’s $2.2bn acquisition of Rapt Therapeutics marks new CEO Luke Miels’ bold opening move, betting on an experimental food allergy drug with blockbuster potential. Trial data due in 2026 will determine if this premium gamble pays off.
FAQ
Q1: What is ozureprubart?
A: Ozureprubart is Rapt Therapeutics’ experimental drug designed to treat food allergies by providing sustained protection rather than just emergency intervention. Trial data is expected in 2026, which will determine its commercial viability.
Q2: Why did GSK pay nearly double Rapt’s share price?
A: GSK paid a premium because ozureprubart addresses a significant unmet medical need in food allergies, a market with few effective treatments. The potential for a best-in-class therapy justified the $58-per-share valuation versus the $33.81 closing price.
Q3: What territories does GSK’s acquisition cover?
A: GSK acquired global rights to ozureprubart excluding mainland China, Hong Kong, Taiwan, and Macau. Those territories remain with Rapt’s Chinese partner, Shanghai Jeyou Pharmaceutical Co.
Q4: Why did GSK shares fall after the announcement?
A: Shares dropped 1.24% as investors likely adopted a wait-and-see approach, wanting to review 2026 trial data before fully backing the $2.2bn investment. Premium acquisitions always carry risk until clinical proof emerges.
Q5: What’s happening with GSK’s HIV venture ViiV Healthcare?
A: Shionogi is buying Pfizer’s 11.7% stake in ViiV for $2.1bn, increasing its own holding to 21.7% whilst GSK retains 78.3%. This simplifies the ownership structure whilst maintaining the partnership’s focus on long-acting HIV treatments.
DISCLAIMER
Effective Date: 15th July 2025
The information provided on this website is for informational and educational purposes only and reflects the personal opinions of the author(s). It is not intended as financial, investment, tax, or legal advice.
We are not certified financial advisers. None of the content on this website constitutes a recommendation to buy, sell, or hold any financial product, asset, or service. You should not rely on any information provided here to make financial decisions.
We strongly recommend that you:
- Conduct your own research and due diligence
- Consult with a qualified financial adviser or professional before making any investment or financial decisions
While we strive to ensure that all information is accurate and up to date, we make no guarantees about the completeness, reliability, or suitability of any content on this site.
By using this website, you acknowledge and agree that we are not responsible for any financial loss, damage, or decisions made based on the content presented.
MORE NEWS
Disclosure & Editorial Standards
MJBurrows is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this website — including articles, calculators, and tools — is for general informational and educational purposes only. It does not constitute personal financial, investment, tax, or legal advice and does not take into account your individual circumstances, financial situation, or objectives.
Nothing on this site is a personal recommendation to buy, sell, hold, or otherwise deal in any financial product, asset, or service. You should always conduct your own research and seek advice from a qualified, FCA-regulated financial adviser before making any financial decisions.
Our calculators produce estimates based on simplified models using HMRC-published rates for the current tax year. They cannot account for every individual circumstance and should not be relied upon as exact figures. Tax rules and rates may change — verify current rates with HMRC or a qualified tax adviser.
Projections are not guarantees. Where our tools show future values (investment growth, pension projections, compound interest), these are hypothetical illustrations based on assumed growth rates. Past performance does not guarantee future results. The value of investments can go down as well as up.
Market data displayed on this site is provided by third-party sources including Twelve Data, Yahoo Finance, and CoinGecko. We do not guarantee the accuracy, completeness, or timeliness of third-party data.
This content is designed for UK residents and reflects UK tax rules, thresholds, and legislation. It may not apply to other jurisdictions.
Using this website does not create a professional-client relationship of any kind. MJBurrows is not responsible for any financial loss, damage, or decision made based on the content presented. By using this site, you accept these terms.
This disclaimer may be updated from time to time without prior notice. Last reviewed: 23 April 2026.
MJBurrows is an independent UK personal finance publication, written and edited by Matthew Burrows. There is no parent company, no investor group, and no advertising sales team — decisions about what to cover and how to frame it are made by Matthew alone. Our full Editorial Policy sets out how the site operates in detail.
Commercial model. As of April 2026, MJBurrows generates no revenue. The site carries no display advertising, no affiliate links, no sponsored content, no paid product placements, and no pay-for-coverage arrangements. If this changes in future, it will be disclosed openly on the Editorial Policy page.
Sources. Articles and tools reference primary sources — HM Revenue & Customs (HMRC), gov.uk, the Bank of England, the Office for National Statistics (ONS), the Financial Conduct Authority (FCA), Companies House, and UK government departmental publications (DWP, Treasury). Calculator data uses HMRC-published rates for the 2026/27 tax year. Market data (tickers, asset prices) is provided by Twelve Data, Yahoo Finance, and CoinGecko.
Verification. Every published article is fact-checked before going live. Numerical claims are traced to their primary source, quotes are checked against the original speaker or document, and calculator outputs are tested against HMRC worked examples. See our verification and accuracy policy for the full process.
Corrections. If you spot an error, please report it via the Corrections page. A three-tier severity system commits to specific response times:
- Tier 1 — Urgent (material reader harm, defamatory statements, regulatory or legal issues): acknowledged within 24 hours, page actioned within 24 hours, correction published within 48 hours of confirmation.
- Tier 2 — High (significant factual errors that misinform readers): acknowledged within 3 working days, correction published within 7 working days of confirmation.
- Tier 3 — Standard (minor factual errors, dated references, missing context): acknowledged within 7 working days, correction published at the next regular content review (within the quarter).
Significant corrections are logged on the public Corrections log.
Updates and review cadence. Calculators are reviewed at least quarterly, plus event-driven updates when HMRC publishes new rates (Budget, Autumn Statement, new tax year). Guides are reviewed at least twice a year, with major rewrites whenever underlying regulation changes. Tax-year-sensitive content is prioritised for review at the April tax-year transition.
Get in touch. For editorial enquiries — corrections, story tips, reader questions — the address is contact@mjburrows.com. The contact page is at mjburrows.com/contact. Every email is read personally by Matthew.
